Apo-1/Fas (CD95) gene polymorphism in Korean hepatocellular carcinoma patients

Korean Journal of Physiology and Pharmacology

Volumn 7, Issue 1, 2003, Pages 29-31

  Kim, Sung Soo ^a   Hong, Seung Jae ^b   Ahn, Yun Gul ^a   Kim, Bong Seog ^a,c   Yuh, Young Jin ^a,d   Han, Kye Young ^a   Lee, Hee Jae ^e   Chung, Joo Ho ^e   Yim, Sung Vin ^a   Cho, Jaeyoung ^f   Park, Yeon Hee ^g  

^a Kangwon National University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Seoul Veterans Hospital   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

^f Seoul National University   (South Korea)

^g Korea Cancer Center Hospital   (South Korea)

Author keywords

Apo 1 Fas (CD95); Apoptosis; Hepatocellular carcinoma; PCR RFLP; Polymorphism

Indexed keywords

FAS ANTIGEN; FAS LIGAND; GENOMIC DNA;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

EID: 0037316275     PISSN: 12264512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Alameddine FM, Zafari AM. Genetic polymorphisms and oxidative stress in heart failure. Congest Heart Fail 8: 157-164, 2002
2. Fan XQ, Guo YJ. Apoptosis in oncoloy. Cell Res 11: 1-7, 2001
3. Farker K, Schotte U, Scheele J, Hoffmann A. Assessment of frequencies of lifestyle factors and polymorphisms of drug-metabolizing enzymes (NAT2, CYP2E1) in human hepatocellular carcinoma (HCC) patients in a department of surgical medicine - a pilot investigation. Int J Clin Pharmacol Ther 40: 120-124, 2002
4. Huang QR, Danis V, Lassere M, Edmonds J, Manolios N. Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford) 38: 645-651, 1999
5. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 34: 577-582, 1997
6. Huang QR, Teutsch SM, Buhler MM, Bennetts BH, Heard RN, Manolios N, Stewart GJ. Evaluation of the apo-1/Fas promoter mva I polymorphism in multiple sclerosis. Mult Scler 6: 14-18, 2000
7. Kim SA, Kim YJ, Choe BK, Lee HJ, Kim JW, Park JD, Kim CJ, Park SJ, Jung JC, Chung JH. Assessment of an Apo-1/Fas promoter polymorphism in Korean schizophrenia patients. Korean J Physiol Pharmacol 6: 131-138, 2002
8. Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY, Yoo NJ. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 32: 250-256, 2001
9. Lee YH, Ji JD, Sohn J, Song GG. Polymorphsims of CTLA-4 exon 1 +49, CTLA-4 promoter -318 and Fas promoter -670 in spondyloarthropathies. Clin Rheumatol 20: 420-422, 2001
10. Maeda T, Kamihira S. Apoptosis, Part II: The role of mutated Fas genes in tumorigenesis. Adv Clin Chem 36: 109-137, 2001
11. Montesano R, Hall J. Environmental causes of human cancers. Eur J Cancer 37: S67-S87, 2001
12. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 28: 441-449, 2001
13. Müllauer L, Gruber P, Sebinger D, Buch J, Wohlfart S, Chott A. Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 488: 211-231, 2001
14. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 33: 29-55, 1999
15. Peter ME, Krammer PH. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis. Curr Opin Immunol 10: 545-551, 1998
16. Rogler CE, Chisari FV. Cellular and molecular mechanisms of hepatocarcinogenesis. Semin Liver Dis 12: 265-278, 1992
17. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 32: 1123-1136, 2000
18. Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW, Shi YF. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 88: 333-347, 2000
19. Sud R, Wells D, Talbot IC, Delhanty JD. Genetic alterations in gastric cancers from British patients. Cancer Genet Cytogenet 126: 111-119, 2001
20. Thorgeirsson SS, Teramoto T, Factor VM. Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis 18: 115-122, 1998
21. Tiemersma EW, Omer RE, Bunschoten A, van't Veer P, Kok FJ, Idris MO, Kadaru AM, Fedail SS, Kampman E. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 10: 785-791, 2001
22. Yu MW, Chiu YH, Yang SY, Santella RM, Chern HD, Liaw YF, Chen CJ. Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Br J Cancer 80: 598-603, 1999
23. Yu MW, Pai CI, Yang SY, Hsiao TJ, Chang HC, Lin SM, Liaw YF, Chen PJ, Chen CJ. Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk. Gut 47: 703-709, 2000
24. Zhang YJ, Chen SY, Chen CJ, Santella RM. Polymorphisms in cyclin D1 gene and hepatocellular carcinoma. Mol Carcinog 33: 125-129, 2002